|
1
|
Gerbes A, Zoulim F, Tilg H, Dufour JF,
Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten
TF, et al: Gut roundtable meeting paper: Selected recent advances
in hepatocellular carcinoma. Gut. 67:380–388. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dhir M, Melin AA, Douaiher J, Lin C, Zhen
WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK and Are C: A
review and update of treatment options and controversies in the
management of hepatocellular carcinoma. Ann Surg. 263:1112–1125.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Franchi L, Eigenbrod T, Muñoz-Planillo R
and Nuñez G: The inflammasome: A caspase-1-activation platform that
regulates immune responses and disease pathogenesis. Nat Immunol.
10:241–247. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kantono M and Guo B: Inflammasomes and
cancer: The dynamic role of the inflammasome in tumor development.
Front Immunol. 8:11322017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He Y, Hara H and Núñez G: Mechanism and
regulation of NLRP3 inflammasome activation. Trends Biochem Sci.
41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Strowig T, Henao-Mejia J, Elinav E and
Flavell R: Inflammasomes in health and disease. Nature.
481:278–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X,
Zhao W, Huai W, Guo P and Han L: Deregulation of the NLRP3
inflammasome in hepatic parenchymal cells during liver cancer
progression. Lab Invest. 94:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chu Q, Jiang Y, Zhang W, Xu C, Du W,
Tuguzbaeva G, Qin Y, Li A, Zhang L, Sun G, et al: Pyroptosis is
involved in the pathogenesis of human hepatocellular carcinoma.
Oncotarget. 7:84658–84665. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheetham SW, Gruhl F, Mattick JS and
Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J
Cancer. 108:2419–2425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mattick JS and Makunin IV: Non-coding RNA.
Hum Mol Genet. 15:R17–R29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui H, Zhang Y, Zhang Q, Chen W, Zhao H
and Liang J: A comprehensive genome-wide analysis of long noncoding
RNA expression profile in hepatocellular carcinoma. Cancer Med.
6:2932–2941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang X, Sun L, Wang L, Yao B, Mo H and
Yang W: lncRNA SNHG7 accelerates the proliferation, migration and
invasion of hepatocellular carcinoma cells via regulating
miR-122-5p and RPL4. Biomed Pharmacother. 118:1093862019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Zeng C, Hu J, Pan Y, Shan Y, Liu B
and Jia L: Long non-coding RNA-SNHG7 acts as a target of miR-34a to
increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in
colorectal cancer progression. J Hematol Oncol. 11:892018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu F, Dong P, Mao Y, Zhao B, Huang Z and
Zheng J: Loss of lncRNA-SNHG7 promotes the suppression of hepatic
stellate cell activation via miR-378a-3p and DVL2. Mol Ther Nucleic
Acids. 17:235–244. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu S, Xu J, Xu X, Hu S, Li B and Li W: The
expression of astrocyte elevated gene-1 in human non-small-cell
lung cancer and its relationship with postoperative chemotherapy
and radiotherapy. Histopathology. 67:817–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huo X, Han S, Wu G, Latchoumanin O, Zhou
G, Hebbard L, George J and Qiao L: Dysregulated long noncoding RNAs
(lncRNAs) in hepatocellular carcinoma: Implications for
tumorigenesis, disease progression, and liver cancer stem cells.
Mol Cancer. 16:1652017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Wang P, Yang X, Wang W, Zhang J, He
Y, Zhang W, Jing T, Wang B and Lin R: SIRT1 inhibits inflammatory
response partly through regulation of NLRP3 inflammasome in
vascular endothelial cells. Mol Immunol. 77:148–156. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rayamajhi M, Zhang Y and Miao EA:
Detection of pyroptosis by measuring released lactate dehydrogenase
activity. Methods Mol Biol. 1040:85–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shan Y, Ma J, Pan Y, Hu J, Liu B and Jia
L: lncRNA SNHG7 sponges miR-216b to promote proliferation and liver
metastasis of colorectal cancer through upregulating GALNT1. Cell
Death Dis. 9:7222018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
She K, Huang J, Zhou H, Huang T, Chen G
and He J: lncRNA-SNHG7 promotes the proliferation, migration and
invasion and inhibits apoptosis of lung cancer cells by enhancing
the FAIM2 expression. Oncol Rep. 36:2673–2680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang MW, Liu J, Liu Q, Xu QH, Li TF, Jin S
and Xia TS: LncRNA SNHG7 promotes the proliferation and inhibits
apoptosis of gastric cancer cells by repressing the P15 and P16
expression. Eur Rev Med Pharmacol Sci. 21:4613–4622.
2017.PubMed/NCBI
|
|
24
|
Qi H, Wen B, Wu Q, Cheng W, Lou J, Wei J,
Huang J, Yao X and Weng G: Long noncoding RNA SNHG7 accelerates
prostate cancer proliferation and cycle progression through cyclin
D1 by sponging miR-503. Biomed Pharmacother. 102:326–332. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren J, Yang Y, Xue J, Xi Z, Hu L, Pan SJ
and Sun Q: Long noncoding RNA SNHG7 promotes the progression and
growth of glioblastoma via inhibition of miR-5095. Biochem Biophys
Res Commun. 496:712–718. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun BZ, Ji DG, Feng ZX and Wang Y: Long
noncoding RNA SNHG7 represses the expression of RBM5 to strengthen
metastasis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci.
23:5699–5704. 2019.PubMed/NCBI
|
|
27
|
Li J, Yang C, Li Y, Chen A, Li L and You
Z: lncRNA GAS5 suppresses ovarian cancer by inducing inflammasome
formation. Biosci Rep. 38(pii): BSR201711502018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang HF, Wang YC and Han YD: MicroRNA-34a
inhibits liver cancer cell growth by reprogramming glucose
metabolism. Mol Med Rep. 17:4483–4489. 2018.PubMed/NCBI
|
|
29
|
Slabáková E, Culig Z, Remšík J and Souček
K: Alternative mechanisms of miR-34a regulation in cancer. Cell
Death Dis. 8:e31002017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X and Kazgan N: Mammalian sirtuins and
energy metabolism. Int J Biol Sci. 7:575–587. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng T, Wang J, Jiang H and Liu L: Hippo
signaling in oval cells and hepatocarcinogenesis. Cancer Lett.
302:91–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang Y and Nicholl MB: Sirtuin 1 in
malignant transformation: Friend or foe? Cancer Lett. 306:10–14.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Portmann S, Fahrner R, Lechleiter A, Keogh
A, Overney S, Laemmle A, Mikami K, Montani M, Tschan MP, Candinas D
and Stroka D: Antitumor effect of SIRT1 inhibition in human HCC
tumor models in vitro and in vivo. Mol Cancer Ther. 12:499–508.
2013. View Article : Google Scholar : PubMed/NCBI
|
